| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | LGT209, NVP-LGT209 |
| Cas No. | |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Lodelcizumab (HV275056) is a research-grade recombinant antibody targeting Proprotein convertase subtilisin/kexin type 9. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Humanized |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | Q8NBP7 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha).
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658
2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796
3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702
4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458
5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827
6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
